Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Lung Institute’s Stem Cell Procedures Show Improved Quality of Life in Recent Reports
  • USA - English


News provided by

Lung Institute

Feb 22, 2017, 15:00 ET

Share this article

Share toX

Share this article

Share toX

Tampa, Fla. (PRWEB) February 22, 2017 -- Stem cell therapy has made significant innovations in the field of regenerative medicine in recent years. The technology is so cutting edge, in fact, the U.S. Food and Drug Administration (FDA) has yet to sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown that this revolutionary field of medicine is now a realistic option for people living with debilitating conditions. Stem cells are being used with promising results to treat orthopedic injuries, inflammatory-based disease and blood-borne cancers – just to name a few. For specific chronic pulmonary conditions, the Lung Institute is the leader in stem cell therapy, and patients are seeing results.

"Since opening our facilities in 2013, the Lung Institute has treated more than 3,000 patients. We are dedicated to providing superior patient-centric care, which we believe contributes to many of our patient success stories. The science behind stem cell therapy is still evolving, but our physicians have developed a safe technique that has helped our patients see results in their everyday lives,” said Dr. Jack Coleman, Jr., M.D, senior medical director for the Lung Institute.

There are reports of successful stem cell cases across the country, including Herbert K., of Keller, TX, who went to the Lung Institute to receive stem cell therapy for chronic obstructive pulmonary disease (COPD), and following two months of initial treatment, he saw an increase in his lung capacity during a pulmonary function test. While every situation is different, Herbert’s case is not unusual, and there are many more with similar stories. To provide additional context, several ongoing and completed studies are available for review on http://ClinicalTrials.gov that address safety and effectiveness of autologous stem cell therapy for a variety of diseases.

Opponents of stem cell therapy argue that there are no conclusive studies that show it works and that stem cell clinics are not approved or regulated under the FDA. A nationally syndicated entertainment medical TV show recently aired a segment on stem cell therapy, featuring guests who argued those points, while also discussing clinics who promise miracle cures.

“The safety and health of our patients are paramount, which is why the Lung Institute has set rigorous standards and put best practices in place at all of our clinic locations. Our Dallas location requires we follow strict IRB guidelines approved by MaGil IRB, which we have implemented at all of our clinics nationwide,” said Lynne Margnelli, executive vice president of the Lung Institute.

MaGil IRB is accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), which means the Lung Institute follows rigorous standards for ethics, quality and protections for human research. As a medical practice, the Lung Institute complies with federal and state regulations. Autologous stem cell procedures like those performed at the Lung Institute fall into an exemption of FDA regulation (Federal Regulatory References 21 CFR 1271.10(a)(2) and 21 CFR 1271.15 (c)).

The Lung Institute’s in-house outcomes summary shows that more than 80 percent of COPD patients studied saw an improvement their quality of life.

“Although we have seen many positive results, we inform new patients that our stem cell therapy procedures are not cures and are not guaranteed. Many of them come to us looking for answers. It’s our responsibility to provide them with quality care that has the best chance at getting them an improved quality of life,” said Margnelli.

The Lung Institute differentiates itself from normative treatments facilities by understanding the importance patient education, communication with external providers, and post-treatment follow-up to support a patient’s continuum of care led by their primary provider. With new innovations in stem-cell technology every day, the Lung Institute continues to push the boundaries of modern medicine to better serve its patients.

For more about Lung Institute patients’ stories, visit: https://lunginstitute.com/testimonials/

For more about Lung Institute's research, visit: https://lunginstitute.com/white-papers/stem-cell-therapy-and-its-effects-on-copd_september-2016-update/

About the Lung Institute:
The Lung Institute is the leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. To date, the organization has treated over 3,000 patients. The Lung Institute’s in-house outcomes summary shows that percent of COPD patients studied saw an improvement in their quality of life. In 2013, the Lung Institute in Tampa, Fla. Opened. Now, the Lung Institute operates clinics in Tampa, Fla.; Nashville, Tenn.; Scottsdale, Ariz.; Pittsburgh, Pa, and Dallas, Texas. For more information, please visit http://www.lunginstitute.com or call (800) 382-8095.

# # #

Ledora Brown, Lung Institute, http://lunginstitute.com, +1 813-644-6127, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.